Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Transition to flexibly dosed paliperidone palmitate in schizophrenia after unsuccessful prior antipsychotic treatment
NL-OMON36637Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2011
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of paliperidone palmitate in schizophrenia, sponsored by Janssen Pharmaceutical. Started Feb 2011; status: active, not recruiting.
02
Drugs
paliperidone palmitate
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NL-OMON36637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36637.